While if we look at the Earnings Track Record, Nektar Therapeutics (NKTR) managed to surpass quarterly earnings per share estimates in 8 of the trailing twelve fiscal quarters, and has a positive trend with an average surprise of 66%. Following the completion of the transaction, the senior vice president now directly owns 45,022 shares in the company, valued at $591,589.08. The stock was trading on above-average volume.
On 02/17/2017 close, Nektar Therapeutics (NASDAQ:NKTR) rose 0.92% to $13.10. The stock now has a Market Cap of $1.98B.
Nektar Therapeutics (NASDAQ:NKTR) is trading up 24.52% versus 12-month low of 10.52 and stands -34.43% lower from its 1-year peak of $19.98. Shares have been recorded at -34.43% separated from the 52-week high of 19.98 and +24.52% away from the 52-week low of 10.52. If you are accessing this piece on another domain, it was illegally copied and republished in violation of USA & global trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/02/20/nektar-therapeutics-nktr-coo-john-nicholson-sells-3237-shares-of-stock.html.
Several brokerages recently weighed in on NKTR. BTIG Research assumed coverage on shares of Nektar Therapeutics in a research note on Friday, January 6th. They issued a "buy" rating and a $21.00 target price on the stock. They issued a "buy" rating and a $22.00 target price on the stock. The company has an average rating of "Buy" and an average target price of $20.67. Jefferies Group LLC increased their target price on Nektar Therapeutics from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, November 7th.
A number of institutional investors have recently made changes to their positions in the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Rothschild Asset Management Inc. raised its position in shares of Nektar Therapeutics by 2.5% in the third quarter. During the trading on 02/17/2017, Company's stock ranged from $64.27 to $65.52. Great West Life Assurance Co. Can raised its position in shares of Nektar Therapeutics by 4.3% in the third quarter. Genesee Valley Trust Co. now owns 12,189 shares of the biopharmaceutical company's stock worth $209,000 after buying an additional 54 shares during the last quarter. Elkfork Partners LLC acquired a new stake in Nektar Therapeutics during the fourth quarter worth $105,000. Strs Ohio raised its position in shares of Nektar Therapeutics by 39.4% in the third quarter. (NASDAQ:CDK) stock have an ABR of 2.20.
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are created to meet unmet medical needs and improve the benefits of drugs for patients.